Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Bionet TherapeuticsROCO:7808 12 Gross Margin % is 45.42% as of Dec. 2025, which is 36% above its 10-year median of 33.49. GuruFocus rates ROCO:7808 with a GF Score™ of 12/100. The stock has 2 warning signs investors should review. Among 732 Biotechnology companies, Bionet Therapeutics ranks worse than 68.99% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Bionet Therapeutics had a gross margin of 45.42% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
Bionet Therapeutics Gross Margin % Related Terms
Bionet Therapeutics Gross Margin % Historical Data
* Premium members only.
The historical data trend for Bionet Therapeutics's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:7808 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, Bionet Therapeutics's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Bionet Therapeutics Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Bionet Therapeutics's Gross Margin % distribution charts can be found below:
* The bar in red indicates where Bionet Therapeutics's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Bionet Therapeutics (ROCO:7808) has a Gross Margin % of 45.42% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on Bionet Therapeutics and its competitors. This is 36% above median its historical median of 33.49. Over the past decade, Bionet Therapeutics' Gross Margin % has ranged from 2.48 to 39.91. According to the industry distribution chart, Bionet Therapeutics ranks #505 out of 732 companies in the Biotechnology industry, placing it in the top 69%.
Is Bionet Therapeutics' Gross Margin % too high?
Bionet Therapeutics' current Gross Margin % of 45.42% is 36% above median its 10-year median of 33.49. Over the past 10 years, this metric has ranged from a low of 2.48 to a high of 39.91. The Biotechnology industry median Gross Margin % is 60.91. Bionet Therapeutics' value of 45.42% is 25.4% below this industry median. Based on the distribution chart, Bionet Therapeutics ranks #505 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Bionet Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Bionet Therapeutics' Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Bionet Therapeutics ranks #505 out of 732 companies for Gross Margin %. This places Bionet Therapeutics in the lower half of its industry. The industry median Gross Margin % is 60.91. Bionet Therapeutics' value of 45.42% is 25.4% below this benchmark. Historically, Bionet Therapeutics' own Gross Margin % has ranged from 2.48 to 39.91 over the past decade. While the company's 10-year median is 33.49 vs. the industry median of 60.91, Bionet Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Bionet Therapeutics's current Gross Margin % of 45.42% is 25.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on Bionet Therapeutics and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Bionet Therapeutics's current Gross Margin % is 45.42%, which is 36% above median its own 10-year median of 33.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Bionet Therapeutics stock overvalued right now?
Bionet Therapeutics (ROCO:7808) has a current Gross Margin % of 45.42%. The current Gross Margin % is 45.42%, which is 36% above median its 10-year median of 33.49 and 25.4% below the Biotechnology industry median of 60.91. Bionet Therapeutics' overall GF Score™ is 12/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For Bionet Therapeutics (ROCO:7808), the current Gross Margin % is 45.42% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Bionet Therapeutics Corp is a patient-focused on regenerative medicinal products, R&D, exosomes, and gene/cell therapy biopharmaceutical company. The group develops, manufactures, and provides regenerative medicine preparations and cellular therapies to meet the evolving health needs of people at different stages of life. It focused on treatments that improve patient outcomes. It provides Cell Therapy Products and CRDMO Services.
12GF Score
Get the complete analysis for ROCO:7808
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:7808 has been successfully added to your 
